Table 1.
Sociodemographic and clinical characteristics of 251 women included, according to menopausal status
| Menopausal status | |||||
|---|---|---|---|---|---|
| All women | Pre-menopausal | Peri-menopasual | Post-menopausal | p | |
| 251 (100%) | 44 (17.5%) | 70 (27.9%) | 137 (54.6%) | ||
| Sociodemographic variables | |||||
| Age (years; median –[IQR]) | 52 (48–55) | 46 (45–48) | 49 (47–52) | 55 (52–57) | < 0.001 |
| Country of origin | |||||
| Spain | 187 (74.5%) | 26 (59.1%) | 53 (75.7%) | 108 (78.8%) | 0.032 |
| Others | 64 (25.5%) | 18 (40.9%) | 17 (24.3%) | 29 (21.2%) | |
| Educational level | |||||
| None or primary | 21 (8.4%) | 2 (4.5%) | 7 (10.0%) | 12 (8.8%) | 0.574 |
| Secondary or university | 230 (91.6%) | 42 (95.5%) | 63 (90.0%) | 125 (91.2%) | |
| Current occupational status | |||||
| Employed | 137 (54.6%) | 24 (54.5%) | 41 (58.6%) | 72 (52.6%) | 0.525 |
| Unemployed | 45 (17.9%) | 11 (25.0%) | 11 (15.7%) | 23 (16.8%) | |
| Other* | 69 (27.5%) | 9 (20.5%) | 18 (25.7%) | 42 (30.7%) | |
| Current partner and cohabitation status | |||||
| Without partner | 106 (42.2%) | 16 (36.4%) | 19 (27.1%) | 71 (51.8%) | 0.004 |
| With partner and living together | 108 (43.0%) | 24 (54.5%) | 35 (50.0%) | 49 (35.8%) | |
| With partner and not living together | 37 (14.7%) | 4 (9.1%) | 16 (22.9%) | 17 (12.4%) | |
| Clinical variables | |||||
| Body mass index (kg/m2) | |||||
| < 18.5 | 15 (6.0%) | 3 (6.8%) | 2 (2.9%) | 10 (7.3%) | 0.482 |
| 18.5–24.9 | 136 (54.2%) | 23 (52.3%) | 39 (55.7%) | 74 (54.0%) | |
| 25–30 | 54 (21.5%) | 10 (22.7%) | 20 (28.6%) | 24 (17.5%) | |
| > 30 | 39 (15.5%) | 6 (13.6%) | 7 (10.0%) | 26 (19.0%) | |
| Unknown | 7 (2.8%) | 2 (4.5%) | 2 (2.9%) | 3 (2.2%) | |
| Body mass index (kg/m2) | 23.7 (21.2–28.0) | 24.0 (22.0–26.7) | 23.8 (21.2–27.7) | 23.6 (21.0–28.7) | 0.982 |
| Hepatitis B | |||||
| Yes | 60 (23.9%) | 6 (13.6%) | 18 (25.7%) | 36 (26.3%) | 0.335 |
| No | 174 (69.3%) | 33 (75.0%) | 47 (67.1%) | 94 (68.6%) | |
| Unknown | 17 (6.8%) | 5 (11.4%) | 5 (7.1%) | 7 (5.1%) | |
| Hepatitis C | |||||
| Yes | 60 (23.9%) | 6 (13.6%) | 16 (22.9%) | 38 (27.7%) | 0.204 |
| No | 179 (71.3%) | 34 (77.3%) | 50 (71.4%) | 95 (69.3%) | |
| Unknown | 12 (4.8%) | 4 (9.1%) | 4 (5.7%) | 4 (2.9%) | |
| Diabetes mellitus | |||||
| Yes | 18 (7.2%) | 2 (4.5%) | 4 (5.7%) | 12 (8.8%) | 0.549 |
| No | 233 (92.8%) | 42 (95.5%) | 66 (94.3%) | 125 (91.2%) | |
| Osteoporosis | |||||
| Yes | 37 (14.7%) | 0 (0.0%) | 7 (10.0%) | 30 (21.9%) | < 0.001 |
| No | 214 (85.3%) | 44 (100.0%) | 63 (90.0%) | 107 (78.1%) | |
| Smoking | |||||
| Current | 115 (45.8%) | 15 (34.1%) | 35 (50.0%) | 65 (47.4%) | 0.215 |
| Never/past | 136 (54.2%) | 29 (65.9%) | 35 (50.0%) | 72 (52.6%) | |
| Alcohol consumption | |||||
| Never/occasional (< 2 times/week) | 202 (80.5%) | 36 (81.8%) | 56 (80.0%) | 110 (80.3%) | 0.969 |
| Frequent (≥ 2 times/week) | 49 (19.5%) | 8 (18.2%) | 14 (20.0%) | 27 (19.7%) | |
| Drug use | |||||
| Never | 154 (61.4%) | 27 (61.4%) | 43 (61.4%) | 84 (61.3%) | 0.522 |
| Sporadic use | 8 (3.2%) | 3 (6.8%) | 3 (4.3%) | 2 (1.5%) | |
| Regular past use | 75 (29.9%) | 13 (29.5%) | 21 (30.0%) | 41 (29.9%) | |
| Regular current use | 14 (5.6%) | 1 (2.3%) | 3 (4.3%) | 10 (7.3%) | |
| Trouble failing asleep the last two weeks | |||||
| Never | 137 (54.6%) | 28 (63.6%) | 44 (62.9%) | 65 (47.4%) | 0.165 |
| Less than twice a week | 29 (11.6%) | 5 (11.4%) | 6 (8.6%) | 18 (13.1%) | |
| More than 3 times a week | 85 (33.9%) | 11 (25.0%) | 20 (28.6%) | 54 (39.4%) | |
| Social support (MOS-SSS-4item) | |||||
| Poor(score < 12) | 43 (17.1%) | 8 (18.2%) | 4 (5.7%) | 31 (22.6%) | 0.009 |
| Normal(score ≥ 12) | 208 (82.9%) | 36 (81.8%) | 66 (94.3%) | 106 (77.4%) | |
| Sexual intercourse during last year | |||||
| Yes | 159 (63.3%) | 33 (75.0%) | 56 (80.0%) | 70 (51.1%) | < 0.001 |
| No | 92 (36.7%) | 11 (25.0%) | 14 (20.0%) | 67 (48.9%) | |
| Age at diagnosis (years; median[IQR]) | 42 (38–46) | 39 (36.5–42) | 40 (36–44) | 45 (39–49) | < 0.001 |
| HIV transmission mode | |||||
| Injecting drug user | 30 (12.0%) | 3 (6.8%) | 10 (14.3%) | 17 (12.4%) | 0.293 |
| Heterosexual | 210 (83.7%) | 37 (84.1%) | 59 (84.3%) | 114 (83.2%) | |
| Others/Unknown | 11 (4.4%) | 4 (9.1%) | 1 (1.4%) | 6 (4.4%) | |
| Time since HIV diagnoses (years) | |||||
| < 5 | 44 (18%) | 10 (22.7%) | 11 (15.7%) | 23 (16.8%) | 0.667 |
| 5–10 | 85 (34%) | 17 (38.6%) | 24 (34.3%) | 44 (32.1%) | |
| > 10 | 122 (49%) | 17 (38.6%) | 35 (50.0%) | 70 (51.1%) | |
| Antiretroviral treatment | |||||
| Yes | 236 (94%) | 42 (95.5%) | 66 (94.3%) | 128 (93.4%) | 0.88 |
| No | 15 (6%) | 2 (4.5%) | 4 (5.7%) | 9 (6.6%) | |
| Time with ART (years) | |||||
| Median (IQR) | 7.5 (4.8–10.5) | 6.8 (4.2–10.1) | 7.8 (5.2–10.3) | 7.5 (4.6–10.6) | 0.471 |
| ART adherence | |||||
| All pills | 222 (94.1%) | 39 (92.9%) | 60 (90.9%) | 123 (96.1%) | 0.407 |
| Most of them | 11 (4.7%) | 3 (7.1%) | 4 (6.1%) | 4 (3.1%) | |
| Half of them or less | 3 (1.3%) | 0 (0.0%) | 2 (3.0%) | 1 (0.8%) | |
| AIDS diagnosis | |||||
| Yes | 52 (20.7%) | 7 (15.9%) | 14 (20.0%) | 31 (22.6%) | 0.623 |
| No | 199 (79.3%) | 37 (84.1%) | 59 (84.3%) | 106 (77.4%) | |
| CD4 count at last visit (cells/µl) | |||||
| < 200 | 7 (2.8%) | 0 (0.0%) | 1 (1.4%) | 6 (4.4%) | 0.484 |
| 200–500 | 60 (23.9%) | 11 (25.0%) | 15 (21.4%) | 34 (24.8%) | |
| > 500 | 184 (73.3%) | 33 (75.0%) | 54 (77.1%) | 97 (70.8%) | |
| Median (IQR) | 720 (491–960) | 663 (500–925.5) | 719.5 (527–959) | 731 (476–1016) | 0.929 |
| Viral load at last visit | |||||
| Undetectable(≤ 200 copies/µl) | 234 (93.2%) | 41 (93.2%) | 68 (97.1%) | 125 (91.2%) | 0.279 |
| Detectable(> 200 copies/µl) | 17 (6.8%) | 3 (6.8%) | 2 (2.9%) | 12 (8.8%) | |
| Women’s health variables | |||||
| Age at menarche (years) | |||||
| < 13 | 98 (39%) | 16 (36.4%) | 28 (40.0%) | 54 (39.4%) | 0.990 |
| ≥ 13 | 149 (59%) | 27 (61.4%) | 41 (58.6%) | 81 (59.1%) | |
| Unknown | 4 (02%) | 1 (2.3%) | 1 (1.4%) | 2 (1.5%) | |
| Number of pregnancies | |||||
| None | 36 (14.3%) | 7 (15.9%) | 13 (18.6%) | 16 (11.7%) | 0.344 |
| 1 or 2 | 114 (45.4%) | 17 (38.6%) | 27 (38.6%) | 70 (51.1%) | |
| ≥ 3 | 101 (40.2%) | 20 (45.5%) | 30 (42.9%) | 51 (37.2%) | |
Bold values are statistically significant
IQR interquartile range, ART antiretroviral therapy, AIDS acquired immunodeficiency syndrome
*Other: retired, housewife, students